Search results
Results from the WOW.Com Content Network
FDA-approved for treatment of myocardial infarction with ST-elevation (STEMI), acute ischemic stroke (AIS), acute massive pulmonary embolism, and central venous access devices (CVAD). [28] Reteplase: FDA-approved for acute myocardial infarction, where it has more convenient administration and faster thrombolysis than alteplase. This is because ...
Tenecteplase, sold under the trade names TNKase, Metalyse and Elaxim, is an enzyme used as a thrombolytic drug.. Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells).
A cerebroprotectant (formerly known as a neuroprotectant) is a drug that is intended to protect the brain after the onset of acute ischemic stroke. [1] As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 drugs have been tested in clinical trials to provide cerebroprotection.
ELIQUIS ® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol ...
A high score corresponds to a greater risk of stroke, while a low score corresponds to a lower risk of stroke. The CHADS 2 score is simple and has been validated by many studies. [ 2 ] In clinical use, the CHADS 2 score (pronounced "chads two") has been superseded by the CHA 2 DS 2 -VASc score ("chads vasc" [ 3 ] ), which gives a better ...
A new study says that type 2 diabetes medications GLP-1 agonists and SGLT2 inhibitors may help lower a stroke survivor’s risk of experiencing a subsequent stroke, heart attack, or death ...
The decision was based on the results of a study that found that Wegovy cut the risk of serious heart problems — including heart attack, stroke and heart-related deaths. Higher-weight patients ...
Prasugrel is associated with a higher bleeding risk compared to clopidogrel but has demonstrated superiority in reducing the composite endpoint of death, recurrent myocardial infarctions and stroke. [4] Prasugrel does not change the risk of death when given to people who have had a STEMI [citation needed] or NSTEMI.